MGRX
Mangoceuticals, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$0.41
+5.30%Aug 4, 2026, 20:05 UTC
Nasdaq granted Mangoceuticals, Inc. a 180-day extension to regain compliance with the minimum bid price requirement, extending the deadline to February 1, 2027.
Source:Jul 30, 2026, 11:00 UTC
Mangoceuticals entered into a definitive business combination agreement with Nuclea Energy Inc. to bring Nuclea's Morpheus microreactor to the public markets.
Jul 30, 2026, 00:00 UTC
Mangocuticals, Inc. terminated Jacob D. Cohen as Chief Executive Officer and appointed Josef Freundorfer as successor, while also appointing Jacob D. Cohen as President and Sagar Sanghera as Executive Chairman and Director.
Jul 2, 2026, 00:00 UTC
MangocEuticals, Inc. completed a private placement of 850,000 shares of restricted common stock to an accredited investor, raising $272,000 at $0.32 per share, exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D.